Therapy for hormone-resistant prostate cancer: no longer a myth

Related Experiment Video

Updated: Nov 1, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

D P Petrylak, B Abi-Rashid

    Cancer Treatment and Research
    |January 1, 1996
    PubMed

    Insights

    Researchers are exploring new cellular targets to treat hormone-refractory disease, potentially extending survival. Further clinical trials are needed to confirm these promising findings in cancer treatment.

    Area of Science:

    • Oncology
    • Cellular Biology
    • Disease Treatment

    Background:

    • Hormone-refractory disease presents significant treatment challenges.
    • Identifying novel cellular targets is crucial for therapeutic advancement.

    Purpose of the Study:

    • To review recent progress in identifying cellular targets for hormone-refractory disease.
    • To assess the potential impact of these targets on patient survival.

    Main Methods:

    • Literature review of studies on cellular targets in hormone-refractory disease.
    • Analysis of data from preclinical and early-phase clinical investigations.

    Main Results:

    • Significant advancements have been made in discovering new cellular targets.
    • Preliminary data suggest potential survival benefits in some cases.

    Conclusions:

    • Current research shows promise for novel therapeutic strategies.
    • Prospective clinical trials are essential to validate efficacy and confirm survival extension.

    More Related Videos

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

    Published on: September 8, 2017

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    Disorders of the Male Reproductive System01:20

    Disorders of the Male Reproductive System

    Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
    Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...